A double-blind, placebo-controlled trial of modafinil for cocaine dependence

• DOI: 10.1016/j.jsat.2011.12.014
• Publication Date: 2012-02-27T12:47:59Z
• Authors: Charles A. Dackis; Kyle M. Kampman; Kevin G. Lynch; Jennifer G. Plebani; Helen M. Pettinati; Thorne Sparkman; Charles P. O'Brien
• Keywords: Cocaine dependence; Benzoylecgonine; Tolerability

This is a randomized, double-blind, placebo-controlled study of modafinil treatment for cocaine dependence. Patients (N = 210) who were actively using cocaine at baseline were randomized to 8 weeks of modafinil (0 mg/day, 200 mg/day, or 400 mg/day) combined with once-weekly cognitive-behavioral therapy. Our primary efficacy measure was cocaine abstinence, based on urine benzoylecgonine (BE) levels, with secondary measures of craving, cocaine withdrawal, retention, and tolerability. We found no significant differences between modafinil and placebo patients on any of these measures. However, there was a significant gender difference in that male patients treated with 400 mg/day tended to be more abstinent than their placebo-treated counterparts (p = .06). Our negative findings might be explained by gender differences and/or inadequate psychosocial treatment intensity in patients with severe cocaine dependence.